Skip to content
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016

NEWTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 95849798. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.

 

Contact:

Justin Renz
(617) 658-0574
jrenz@karyopharm.com

Gina Nugent
(617) 460-3579
nugentcomm@aol.com
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.